According to the Vision Research Reports, the Global Pharmaceutical Intermediates market size is projected to reach US$ 53 billion by 2030.
Download Exclusive Sample of Report@ https://www.visionresearchreports.com/report/sample/38525
Rise in prevalence of chronic diseases, focus on research & development by key players and business strategies adopted by key players are the key factors projected to fuel the growth of the global pharmaceutical intermediates market during the forecast period.
The demand for pharmaceutical intermediates majorly depends on the rise in the demand for essential drugs to treat chronic diseases. The growing prevalence of contagious diseases, principally in Southeast Asia, is likely to fuel the demand for APIs in the following years, ultimately propelling the pharmaceutical intermediates market. Moreover, advancements in technologies such as high throughput, bioinformatics, and combinatorial chemistry for better drug candidate identification are increasing the demand for pharmaceutical intermediates for research purposes. Hence, owing to rising production and research exercises in the pharmaceutical industry, the usage of pharmaceutical intermediates is expected to witness a constant growth during the projected period.
Focus on Research & Development to Propel Market
The development of innovative and effective health products for humans has increased in the past few decades. Key players are gearing up to introduce new drugs in the market. The research-based pharmaceutical industry can play a critical role in restoring growth and ensuring future competitiveness in an advancing global economy. The high investment in R&D capabilities and infrastructure by the industries and governments alike is anticipated to create lucrative opportunities in the global pharmaceutical intermediates market. The rising R&D pipeline of India-based companies presents significant in-licensing opportunities for global companies.
Why pharmaceutical intermediates?
Pharmaceutical intermediates are drugs used as raw materials in the production of bulk drugs. Moreover, they are widely used to refer to a material created during the synthesis of an active pharmaceutical ingredient (API) before the processing of becoming an API. Pharmaceutical intermediates are usually formed using high-grade raw materials. These intermediates are widely used in the pharmaceutical and cosmetic industries. The rising demand in these industries is expanding the global pharmaceutical intermediates market. Pharmaceutical intermediates are popularly used for research and development in the pharmaceutical industry. The pharmaceutical intermediates are increasingly being produced using raw materials such as coal tar or petroleum to manufacture pesticides, pharmaceuticals, resins, additives, plasticizers, etc. However, several intermediates can be produced in organic synthesis, and be used in creating various drugs and products.
Report Scope
In terms of product, the global pharmaceutical intermediates market has been bifurcated into bulk drug intermediate and custom intermediate. The bulk drug intermediate segment has been split into chiral intermediate and achiral intermediate.
Based on application, the global pharmaceutical intermediates market has been segregated into cardiology, oncology, endocrinology, infectious diseases, orthopedics, neurology, gastroenterology, dermatology, inflammatory & pain management, ophthalmology, and others. Changes in lifestyle i.e., increase in consumption of tobacco and burden of cancer fuels the growth of the oncology segment.
In terms of end user, the global pharmaceutical intermediates market has been divided into pharmaceutical & biotechnology companies and CROs & CMOs. The fragmented structure of the CRO industry has led to an increase in strategic alliances, acquisitions, joint ventures, and other partnership deals as companies attempt to expand their service offerings and geographical presence.
In terms of region, the North America is expected to account for a significant share of the global pharmaceutical intermediates market during the forecast period. The growth of the pharmaceutical intermediates market in the region can be attributed to rise in access to healthcare and increase in incidence of chronic diseases. According to the World Health Organization, stroke, diabetes mellitus, COPD, and lower respiratory diseases were the top causes of death in 2020.
The market in Asia Pacific is likely to expand at a high CAGR from 2021 to 2030. The increase in the geriatric population is projected to boost the market in the region.
Key Players
The report provides profiles of leading players operating in the global pharmaceutical intermediates market. These include BASF SE, Lonza Group, Evonik Industries AG, Cambrex Corporation, DSM, Aceto, Albemarle Corporation, Vertellus, Chemcon Speciality Chemicals Ltd., Chiracon GmbH, and A. R. Life Sciences Private Limited.
Market Segmentation
Market By Product
- Bulk Drug Intermediate
-
- Chiral Intermediate
- Achiral Intermediate
-
- Custom Intermediate
Market By Application
-
- Cardiology
- Oncology
- Endocrinology
- Infectious Diseases
- Orthopedics
- Neurology
- Gastroenterology
- Dermatology
- Inflammatory & Pain Management
- Ophthalmology
- Others
Market By End User
-
- Pharmaceutical & Biotechnology Companies
- CROs & CMOs
Market By Region
-
- North America
- U.S.
- Canada
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Rest of the Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Australia & New Zealand
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- GCC Countries
- South Africa
- Rest of Middle East & Africa
- North America
Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/38525
Research Methodology
The research methodology adopted by analysts for compiling the global pharmaceutical intermediates market report is based on detailed primary as well as secondary research. With the help of in-depth insights of the market-affiliated information that is obtained and legitimated by market-admissible resources, analysts have offered riveting observations and authentic forecasts for the global market.
During the primary research phase, analysts interviewed market stakeholders, investors, brand managers, vice presidents, and sales and marketing managers. Based on data obtained through interviews of genuine resources, analysts have emphasized the changing scenario of the global market.
For secondary research, analysts scrutinized numerous annual report publications, white papers, market association publications, and company websites to obtain the necessary understanding of the global pharmaceutical intermediates market.
Table of Contents
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Pharmaceutical Intermediates Market, By Product
7.1. Pharmaceutical Intermediates Market, by Product, 2021-2030
7.1.1. Bulk Drug Intermediate
7.1.1.1. Market Revenue and Forecast (2016-2030)
7.1.2. Custom Intermediate
7.1.2.1. Market Revenue and Forecast (2016-2030)
Chapter 8. Global Pharmaceutical Intermediates Market, By Application
8.1. Pharmaceutical Intermediates Market, by Application, 2021-2030
8.1.1. Cardiology
8.1.1.1. Market Revenue and Forecast (2016-2030)
8.1.2. Oncology
8.1.2.1. Market Revenue and Forecast (2016-2030)
8.1.3. Endocrinology
8.1.3.1. Market Revenue and Forecast (2016-2030)
8.1.4. Infectious Diseases
8.1.4.1. Market Revenue and Forecast (2016-2030)
8.1.5. Orthopedics
8.1.5.1. Market Revenue and Forecast (2016-2030)
8.1.6. Neurology
8.1.6.1. Market Revenue and Forecast (2016-2030)
8.1.7. Gastroenterology
8.1.7.1. Market Revenue and Forecast (2016-2030)
8.1.8. Dermatology
8.1.8.1. Market Revenue and Forecast (2016-2030)
8.1.9. Inflammatory & Pain Management
8.1.9.1. Market Revenue and Forecast (2016-2030)
8.1.10. Ophthalmology
8.1.10.1. Market Revenue and Forecast (2016-2030)
8.1.11. Others
8.1.11.1. Market Revenue and Forecast (2016-2030)
Chapter 9. Global Pharmaceutical Intermediates Market, By End User
9.1. Pharmaceutical Intermediates Market, by End User, 2021-2030
9.1.1. Pharmaceutical & Biotechnology Companies
9.1.1.1. Market Revenue and Forecast (2016-2030)
9.1.2. CROs & CMOs
9.1.2.1. Market Revenue and Forecast (2016-2030)
Chapter 10.Global Pharmaceutical Intermediates Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Product (2016-2030)
10.1.2. Market Revenue and Forecast, by Application (2016-2030)
10.1.3. Market Revenue and Forecast, by End User (2016-2030)
10.1.4. U.S.
10.1.4.1. Market Revenue and Forecast, by Product (2016-2030)
10.1.4.2. Market Revenue and Forecast, by Application (2016-2030)
10.1.4.3. Market Revenue and Forecast, by End User (2016-2030)
10.1.5. Rest of North America
10.1.5.1. Market Revenue and Forecast, by Product (2016-2030)
10.1.5.2. Market Revenue and Forecast, by Application (2016-2030)
10.1.5.3. Market Revenue and Forecast, by End User (2016-2030)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Product (2016-2030)
10.2.2. Market Revenue and Forecast, by Application (2016-2030)
10.2.3. Market Revenue and Forecast, by End User (2016-2030)
10.2.4. UK
10.2.4.1. Market Revenue and Forecast, by Product (2016-2030)
10.2.4.2. Market Revenue and Forecast, by Application (2016-2030)
10.2.4.3. Market Revenue and Forecast, by End User (2016-2030)
10.2.5. Germany
10.2.5.1. Market Revenue and Forecast, by Product (2016-2030)
10.2.5.2. Market Revenue and Forecast, by Application (2016-2030)
10.2.5.3. Market Revenue and Forecast, by End User (2016-2030)
10.2.6. France
10.2.6.1. Market Revenue and Forecast, by Product (2016-2030)
10.2.6.2. Market Revenue and Forecast, by Application (2016-2030)
10.2.6.3. Market Revenue and Forecast, by End User (2016-2030)
10.2.7. Rest of Europe
10.2.7.1. Market Revenue and Forecast, by Product (2016-2030)
10.2.7.2. Market Revenue and Forecast, by Application (2016-2030)
10.2.7.3. Market Revenue and Forecast, by End User (2016-2030)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Product (2016-2030)
10.3.2. Market Revenue and Forecast, by Application (2016-2030)
10.3.3. Market Revenue and Forecast, by End User (2016-2030)
10.3.4. India
10.3.4.1. Market Revenue and Forecast, by Product (2016-2030)
10.3.4.2. Market Revenue and Forecast, by Application (2016-2030)
10.3.4.3. Market Revenue and Forecast, by End User (2016-2030)
10.3.5. China
10.3.5.1. Market Revenue and Forecast, by Product (2016-2030)
10.3.5.2. Market Revenue and Forecast, by Application (2016-2030)
10.3.5.3. Market Revenue and Forecast, by End User (2016-2030)
10.3.6. Japan
10.3.6.1. Market Revenue and Forecast, by Product (2016-2030)
10.3.6.2. Market Revenue and Forecast, by Application (2016-2030)
10.3.6.3. Market Revenue and Forecast, by End User (2016-2030)
10.3.7. Rest of APAC
10.3.7.1. Market Revenue and Forecast, by Product (2016-2030)
10.3.7.2. Market Revenue and Forecast, by Application (2016-2030)
10.3.7.3. Market Revenue and Forecast, by End User (2016-2030)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Product (2016-2030)
10.4.2. Market Revenue and Forecast, by Application (2016-2030)
10.4.3. Market Revenue and Forecast, by End User (2016-2030)
10.4.4. GCC
10.4.4.1. Market Revenue and Forecast, by Product (2016-2030)
10.4.4.2. Market Revenue and Forecast, by Application (2016-2030)
10.4.4.3. Market Revenue and Forecast, by End User (2016-2030)
10.4.5. North Africa
10.4.5.1. Market Revenue and Forecast, by Product (2016-2030)
10.4.5.2. Market Revenue and Forecast, by Application (2016-2030)
10.4.5.3. Market Revenue and Forecast, by End User (2016-2030)
10.4.6. South Africa
10.4.6.1. Market Revenue and Forecast, by Product (2016-2030)
10.4.6.2. Market Revenue and Forecast, by Application (2016-2030)
10.4.6.3. Market Revenue and Forecast, by End User (2016-2030)
10.4.7. Rest of MEA
10.4.7.1. Market Revenue and Forecast, by Product (2016-2030)
10.4.7.2. Market Revenue and Forecast, by Application (2016-2030)
10.4.7.3. Market Revenue and Forecast, by End User (2016-2030)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Product (2016-2030)
10.5.2. Market Revenue and Forecast, by Application (2016-2030)
10.5.3. Market Revenue and Forecast, by End User (2016-2030)
10.5.4. Brazil
10.5.4.1. Market Revenue and Forecast, by Product (2016-2030)
10.5.4.2. Market Revenue and Forecast, by Application (2016-2030)
10.5.4.3. Market Revenue and Forecast, by End User (2016-2030)
10.5.5. Rest of LATAM
10.5.5.1. Market Revenue and Forecast, by Product (2016-2030)
10.5.5.2. Market Revenue and Forecast, by Application (2016-2030)
10.5.5.3. Market Revenue and Forecast, by End User (2016-2030)
Chapter 11. Company Profiles
11.1. BASF SE
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Lonza Group
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Evonik Industries AG
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Cambrex Corporation
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. DSM
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Aceto
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Albemarle Corporation
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Vertellus
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Chemcon Speciality Chemicals Ltd.
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Chiracon GmbH
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/38525
Contact Us:
Vision Research Reports
Call: +1 9197 992 333
